COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (mCRPC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01400555
Recruitment Status : Completed
First Posted : July 22, 2011
Last Update Posted : March 21, 2018
Information provided by (Responsible Party):
Cougar Biotechnology, Inc.

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : May 12, 2014
Actual Study Completion Date : February 28, 2017